Apixaban or Enoxaparin After Head and Neck Cancer Surgery (NCT07189897)
An Open-label Pilot Study to Evaluate Medication Satisfaction With Apixaban Versus Enoxaparin for Thrombosis Prevention After Head and Neck Cancer Surgery
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine? Researchers will compare 2 groups: One group will take apixaban (a pill taken twice a day) for 10 days after surgery. The other group will take enoxaparin (a shot given once a day) for 10 days after surgery. Participants will: Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks How long will participation last? About 4 months from surgery through the last follow-up visit.
Who can join: Review the eligibility criteria below.
Location: SUNY Upstate — Syracuse, New York
Age range: 18 Years to 89 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- SUNY Upstate — Syracuse, New York
📞 Contact the Study Coordinator
Phone: (315) 464-5980
Email: abernatL@upstate.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Venous Thromboembolism
- Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery — Charleston, South Carolina
- Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism — Basking Ridge, New Jersey
- Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty — Miami, Florida
- Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters — Halifax, Nova Scotia
- DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis — Scottsdale, Arizona
- Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis — Ottawa, Ontario
Explore by condition: All Venous Thromboembolism clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.